AlphaValue/Baader Europe on Wednesday downgraded French biopharmaceutical company Ipsen (IPN.PA) to add from buy, while raising its price target to 212 euros from 206 euros.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)